Enrique Grande (MD Anderson Cancer Center) discusses evolving immunotherapy combination strategies in the first line treatment of urothelial cancer at ESMO 2019.
Questions
1. In which patients with urothelial cancer is immunotherapy indicated as first-line therapy? (0:04)
2. How can we improve response rates to immune checkpoint inhibitors in patients with urothelial cancer? (0:09)
3. Which combined treatment regimens involving immune checkpoint inhibitors appear most promising? (1:10)
4. What novel agents might be combined with immune checkpoint inhibitors to further enhance responses? (1:51)
5. What do you expect to be the next major breakthrough in urothelial cancer? (2:31)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Enrique Grande has acted as an advisor for Roche, BMS, Pfizer, Eisai, Eusa Pharma, Janssen, Astellas, Bayer, Pierre Fabre, MSD and AstraZeneca.
